Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by PeteZerriaon Jan 08, 2023 11:26pm
135 Views
Post# 35210328

RE:RE:RE:RE:Open market purchase

RE:RE:RE:RE:Open market purchase

Another option is to search the SEDI database (System for Electronic Disclosure by Insiders) run by the Canadian Securities Administrators.

https://www.sedi.ca/sedi/SVTItdController?locale=en_CA

 

Just enter “Coffey” and other search info and you should get to an 8-page summary of every single insider transaction by Matt Coffey since 2003. You’ll find that he currently owns 96,333 common shares and about 1.354m options. You can do this for all the rest of ONC’s officers and board members. Bernd Seizinger owns about 315,000 common shares and 65,000 options.

 

I’ve been mostly a lurker here for a number of years and only because of the handful of knowledgeable posters like Noteable, CF, westcoast, fox7, Proboscices, and some others. First came across ONCY at a BioPub webinar featuring Dr. Coffey (June 2018) and have owned shares ever since, though I sold much of my position in 2020/21. More recently I’ve been accumulating as the positive news keeps piling up. I doubt I would have started buying shares again last summer without the insights of the braintrust here. Trolls are blocked immediately.

<< Previous
Bullboard Posts
Next >>